<DOC>
	<DOCNO>NCT02178150</DOCNO>
	<brief_summary>This double-blind randomized clinical trial start June 2014 end June 2015 Isfahan city . Serum insulin level consider key variable sample size calculate 70 person ( 35 person control group 35 person patient group ) . Patient group receive magnesium supplement ( 250 milligram ) group receive placebo similar magnesium tablet color , odor appearance 8 week . All subject complete 4 physical activity 4 dietary record . Outcome measurement include sex hormone level , metabolic inflammatory profile measure begin end study well anthropetric measurement .</brief_summary>
	<brief_title>Effect Magnesium Supplementation Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Magnesium Oxide</mesh_term>
	<criteria>Having PCOS accord Rotterdam criterion , Age 2045 year , Lack pregnancy lactation , Not certain regime last 3 month , Nonsmoking , Not disease , include : diabetes , cardiovascular , hepatic , renal thyroid , Not take supplement , Being overweight ( Kg / 25 â‰¤ BMI ) Hormone Therapy , Pregnancy lactation study , Severe weight loss ( 2.5 kg per month ) study</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Magnesium</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Lipid profile</keyword>
	<keyword>Sex hormone</keyword>
	<keyword>Inflammatory factor</keyword>
</DOC>